Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 9, 2006, Pages 1598-1606

  Lou, Jianrong ^a,b   Fatima, Naheed ^a,b   Xiao, Zhen ^c   Stauffer, Stacy ^a   Smythers, Gary ^d   Greenwald, Peter ^a   Ali, Iqbal Unnisa ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Basic Research Laboratory   (United States)

^c Laboratory of Proteomics and Analytical Technologies   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CHAPERONE; CYCLOOXYGENASE 2; MESSENGER RNA;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PREVENTION; CELL FUNCTION; CELL PROLIFERATION; CELL STRAIN HCT116; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFICACY; DRUG INHIBITION; GLYCOLYSIS; HUMAN; HUMAN CELL; MASS SPECTROMETER; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

BLOTTING, WESTERN; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOPHILIN A; GLYCOLYSIS; HCT116 CELLS; HUMANS; NEOPLASM PROTEINS; PEROXIDASES; PROTEOMICS; PYRAZOLES; REPRESSOR PROTEINS; SULFONAMIDES;

EID: 33749340957     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0216     Document Type: Article

References (54)

1. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
2. Parente L, Perretti M. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol 2003;65:153-9.
3. Kiefer JR, Pawlitz JL, Moreland KT, et al. Structural insights into the stereochemistry of the cyclooxygenase reaction. Nature 2000;405:97-101.
4. Park H, Lee S. Free energy perturbation approach to the critical assessment of selective cyclooxygenase-2 inhibitors. J Comput Aided Mol Des 2005;19:17-31.
5. Jacoby RF, Seibert K, Cole CE, et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-4.
6. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
7. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
8. Grosch S, Tegeder I, Niederberger E, et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001;15:2742-4.
9. Yamazaki R, Kusunoki N, Matsuzaki T, et al. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 2002;531:278-84.
10. Hsu AL, Ching TT, Wang DS, et al. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000;275:11397-403.
11. Maier TJ, Janssen A, Schmidt R, et al. Targeting the β-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J 2005;19:1353-5.
12. Maier TJ, Schilling K, Schmidt R, et al. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 2001;67:1469-78.
13. Waskewich C, Blumenthal RD, Li H, et al. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 2002;62:2029-33.
14. Patel MI, Subbaramaiah K, Du B, et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005;11:1999-2007.
15. Williams CS, Watson AJ, Sheng H, et al. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000;60:6045-51.
16. Schroeder CP, Yang P, Newman RA, et al. Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib. Cancer Biol Ther 2004;3:847-52.
17. Kardosh A, Soriano N, Liu YT, et al. Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood 2005;106:4330-8.
18. Kardosh A, Blumenthal M, Wang WJ, et al. Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol Ther 2004;3:55-62.
19. Ding H, Han C, Zhu J, et al. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer 2005;113:803-10.
20. Zhu J, Huang JW, Tseng PH, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 2004;64:4309-18.
21. Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 2005;382:669-78.
22. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997;18:2071-7.
23. Narayanan BA, Condon MS, Bosland MC, et al. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin Cancer Res 2003;9:3503-13.
24. Sperandio da Silva GM, Lima LM, Fraga CA, et al. The molecular basis for coxib inhibition of p38α MAP kinase. Bioorg Med Chem Lett 2005;15:3506-9.
25. Takahashi T, Ogawa Y, Kitaoka K, et al. Selective COX-2 inhibitor regulates the MAP kinase signaling pathway in human osteoarthritic chondrocytes after induction of nitric oxide. Int J Mol Med 2005;15:213-9.
26. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 2003;37:179-92.
27. Ferrandina G, Ranelletti FO, Legge F, et al. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. Clin Cancer Res 2003;9:4324-31.
28. Sun SY, Schroeder CP, Yue P, et al. Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations. Cancer Biol Ther 2005;4:407-13.
29. Buecher B, Bouancheau D, Broquet A, et al. Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines. Anticancer Res 2005;25:225-33.
30. Chow HH, Anavy N, Salazar D, et al. Determination of celecoxib in human plasma using solid-phase extraction and high-performance liquid chromatography. J Pharm Biomed Anal 2004;34:167-74.
31. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9.
32. Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 2004;84:1014-20.
33. Ellis RJ. Molecular chaperones: pathways and networks. Curr Biol 1999;9:R137-9.
34. Uramoto H, Sugio K, Oyama T, et al. Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer 2005;49:55-62.
35. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
36. Ramanathan RK, Trump DL, Eiseman JL, et al. Phase I pharmacokinetic- pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005;11:3385-91.
37. Wang S, Nath N, Adlam M, et al. Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene 1999;18:3501-10.
38. Manjeshwar S, Branam DE, Lerner MR, et al. Tumor suppression by the prohibitin gene 3′ untranslated region RNA in human breast cancer. Cancer Res 2003;63:5251-6.
39. Sato T, Sakamoto T, Takita K, et al. The human prohibitin (PHB) gene family and its somatic mutations in human tumors. Genomics 1993;17:762-4.
40. Butterfield LH, Merino A, Golub SH, et al. From cytoprotection to tumor suppression: the multifactorial role of peroxiredoxins. Antioxid Redox Signal 1999;1:385-402.
41. Immenschuh S, Baumgart-Vogt E. Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid Redox Signal 2005;7:768-77.
42. Shaw PE. Peptidyl-prolyl isomerases: a new twist to transcription. EMBO Rep 2002;3:521-6.
43. Galat A. Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity-targets-functions. Curr Top Med Chem 2003;3:1315-47.
44. Melle C, Osterloh D, Ernst G, et al. Identification of proteins from colorectal cancer tissue by two-dimensional gel electrophoresis and SELDI mass spectrometry. Int J Mol Med 2005;16:11-7.
45. Campa MJ, Wang MZ, Howard B, Fitzgerald MC, Patz EF, Jr. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res 2003;63:1652-6.
46. Shyu AB, Wilkinson MF. The double lives of shuttling mRNA binding proteins. Cell 2000;102:135-8.
47. Pino I, Pio R, Toledo G, et al. Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer 2003;41:131-43.
48. Rogers GW, Komar AA, Merrick WC. eIF4A: the godfather of the DEAD box helicases. Prog Nucleic Acid Res Mol Biol 2002;72:307-31.
49. Caraglia M, Marra M, Giuberti G, et al. The role of eukaryotic initiation factor 5A in the control of cell proliferation and apoptosis. Amino Acids 2001;20:91-104.
50. Lamberti A, Caraglia M, Longo O, et al. The translation elongation factor 1A in tumorigenesis, signal transduction and apoptosis: review article. Amino Acids 2004;26:443-8.
51. Srivastava M, Pollard HB. Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J 1999;13:1911-22.
52. 2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 2005;6:449-61.
53. Chakravarti D, Hong R. SET-ting the stage for life and death. Cell 2003;112:589-91.
54. Beaud G, Sharif A, Topa-Masse A, et al. Ribosomal protein S2/Sa kinase purified from HeLa cells infected with vaccinia virus corresponds to the B1R protein kinase and phosphorylates in vitro the viral ssDNA-binding protein. J Gen Virol 1994;75:283-93.